Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0059 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0037 | 0.2407 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0029 | 0 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0059 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0059 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0059 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0059 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0059 | 1 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.003 | 0.0151 | 0.0151 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0059 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0059 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0059 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0059 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0059 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0059 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0059 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0059 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0052 | 0.7743 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0037 | 0.2407 | 0.2407 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0059 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0059 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0052 | 0.7743 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0059 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0029 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0059 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.5 uM | Inhibitory concentration against Inducible nitric oxide synthase | ChEMBL. | 15501067 |
IC50 (binding) | = 0.5 uM | Inhibitory concentration against Inducible nitric oxide synthase | ChEMBL. | 15501067 |
IC50 (binding) | = 1.2 uM | Inhibitory concentration against Neuronal nitric oxide synthase | ChEMBL. | 15501067 |
IC50 (binding) | = 1.2 uM | Inhibitory concentration against Neuronal nitric oxide synthase | ChEMBL. | 15501067 |
IC50 (binding) | = 77 uM | Inhibitory concentration against Endothelial nitric oxide synthase | ChEMBL. | 15501067 |
IC50 (binding) | = 77 uM | Inhibitory concentration against Endothelial nitric oxide synthase | ChEMBL. | 15501067 |
Selectivity (binding) | = 2.6 | Ratio of inhibitory concentration against Endothelial nitric oxide synthase to Neuronal nitric oxide synthase | ChEMBL. | 15501067 |
Selectivity (binding) | = 164 | Ratio of inhibitory concentration against Endothelial nitric oxide synthase to Inducible nitric oxide synthase | ChEMBL. | 15501067 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.